Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 16/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.37 |
| ▸ | PDE4A | P27815 | 9/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916480 | 0.95 | PDE4B (0.38) | MEN1KMT2APDE4DPDE4BPDE4A | |
| SCHEMBL5048063 | 0.95 | PDE4B (0.38) | MEN1KMT2APDE4DPDE4BPDE4A | |
| SCHEMBL917169 | 0.93 | PDE4D (0.38) | MEN1KMT2APDE4DPDE4BPDE4A | |
| SCHEMBL4140485 | 0.91 | PDE4D (0.40) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL916979 | 0.91 | PDE4B (0.39) | MEN1KMT2APDE4DPDE4BPDE4A | |
| SCHEMBL3843402 | 0.91 | PDE4B (0.37) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL917973 | 0.89 | PDE4D (0.41) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL917232 | 0.89 | PDE4D (0.36) | MEN1KMT2APDE4DPDE4BPDE4A | |
| SCHEMBL3843401 | 0.89 | PDE4B (0.38) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL917619 | 0.88 | PDE4D (0.42) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | claimed |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | disclosed |
| EP-2086948-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | Ranbaxy Laboratories Limited (IN) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008035315-A9 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LAB LTD (IN) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008035315-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | PDE4A, PDE4B, PDE4C | MEN1 4688/4885KMT2A 4445/4885PDE4D 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.